Cardinal Health (CAH) – Investment Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Cardinal Health (NYSE: CAH):

  • 7/13/2017 – Cardinal Health had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $87.00 price target on the stock, up previously from $81.00.
  • 7/11/2017 – Cardinal Health was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/4/2017 – Cardinal Health had its “outperform” rating reaffirmed by analysts at Evercore ISI.
  • 7/4/2017 – Cardinal Health was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Cardinal Health ended third-quarter fiscal 2017 on a solid note, courtesy of encouraging performance in the Medical segment. However, revenues missed the estimate mark in the quarter. Profits at the Pharmaceutical segment were hurt by generic pharmaceutical pricing and the loss of a major Pharmaceutical Distribution customer. Over the past one year, the company has underperformed the broader industry with respect to price. Increasing generic pricing pressure is a major headwind at the moment. Moreover, intensifying competition and customer concentration are other bottlenecks. Sluggish macroeconomic situations and a tough product pricing environment are also likely to dent growth. The company is banking on strategic buyouts, joint ventures and supply agreements to drive growth. Despite the strong prospects, integration risks are likely to mar the company's bottom line in the near term.”
  • 6/20/2017 – Cardinal Health was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Cardinal Health ended third-quarter fiscal 2017 on a solid note, courtesy of encouraging performance in the Medical segment. However, revenues missed the estimate mark in the quarter. Profits at the Pharmaceutical segment were hurt by generic pharmaceutical pricing and the loss of a major Pharmaceutical Distribution customer. Over the past one year, the company has underperformed the broader industry with respect to price. Increasing generic pricing pressure is a major headwind at the moment. Moreover, intensifying competition and customer concentration are other bottlenecks. Sluggish macroeconomic situations and a tough product pricing environment are also likely to dent growth. The company is banking on strategic buyouts, joint ventures and supply agreements to drive growth. Despite the strong prospects, integration risks are likely to mar the company's bottom line in the near term.”
  • 6/13/2017 – Cardinal Health was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $77.92 price target on the stock.
  • 6/7/2017 – Cardinal Health was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $77.92 price target on the stock.
  • 6/2/2017 – Cardinal Health was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 6/1/2017 – Cardinal Health was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $77.92 price target on the stock.

Shares of Cardinal Health, Inc. (CAH) traded down 0.03% during trading on Monday, reaching $78.09. 1,459,140 shares of the company’s stock were exchanged. The stock has a market capitalization of $24.67 billion, a PE ratio of 18.64 and a beta of 0.81. The company’s 50-day moving average is $75.06 and its 200 day moving average is $76.65. Cardinal Health, Inc. has a 52 week low of $62.70 and a 52 week high of $85.52.

Cardinal Health (NYSE:CAH) last announced its quarterly earnings results on Monday, May 1st. The company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.07. Cardinal Health had a net margin of 1.05% and a return on equity of 25.78%. The company had revenue of $31.82 billion during the quarter, compared to the consensus estimate of $32.30 billion. During the same quarter in the previous year, the company posted $1.43 earnings per share. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. On average, analysts forecast that Cardinal Health, Inc. will post $5.35 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Saturday, July 15th. Stockholders of record on Monday, July 3rd were issued a dividend of $0.4624 per share. This is an increase from Cardinal Health’s previous quarterly dividend of $0.45. The ex-dividend date of this dividend was Thursday, June 29th. This represents a $1.85 annualized dividend and a dividend yield of 2.37%. Cardinal Health’s payout ratio is 44.05%.

In related news, CEO of Cardinal Health’s pharmaceutical segment Jon L. Giacomin sold 23,270 shares of Cardinal Health stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $72.87, for a total transaction of $1,695,684.90. Following the sale, the insider now directly owns 55,440 shares in the company, valued at $4,039,912.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.94% of the company’s stock.

Cardinal Health, Inc is a healthcare services and products company. The Company operates through two segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products. This segment also operates nuclear pharmacies and cyclotron facilities; provides pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers, and provides services to healthcare companies.

Receive News & Ratings for Cardinal Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Shares at Radius Jump as Bone Drug of Amgen Has Setback


Leave a Reply

© 2006-2017 Ticker Report. Google+.